[ad_1]
Prevenció,
Inc. announces today data confirming the high accuracy of its
HART CVE multi-protein test driven by AI to predict cardiovascular disease
Events (CVE) and CAD HART Test for the Diagnosis of Coronary Artery Disease
(CAD). Researchers believe these important results, presented on March 17
at the 2019 Scientific Sessions of the American College of Cardiology (ACC) at
New Orleans, demonstrate the robustness and accuracy of these tests. the
New data from two additional hospitals confirm results previously obtained
published by Mbadachusetts General Hospital and Dr. James Januzzi.
HART CVE the data was presented as "Validation of a new system based on AI
Multi-biomarker panel for accurate prediction of cardiovascular events
Occurred in patients with suspicion of myocardial infarction. "The study was
led by the University Heart Center in Hamburg, Germany and led by
Dr. Dirk Westermann, Head of the Structural Heart Program. In this
study, 748 patients presenting themselves to the emergency suspected of having
a heart attack were followed for one year to badess future heart disease.
events, including heart attack and cardiac death. HART CVE from Prevencio
had great accuracy in predicting future cardiac events. The results
included a surface under operating curve (AUC) of 0.86, a high value
negative predictive value of 99.4% and sensitivity of 86.4%.
Commenting on the study, Dr. Westermann said: "We were impressed by
the high accuracy of the HART CVE test and look forward to publishing
the data later this year as well as the presentation of robust data on HART CAD
during the scientific sessions of the European Society of Cardiology in September. "
Westermann added: "Artificial intelligence and the multi-protein approach
is new in cardiology and our data demonstrate the power of HART
platform developed by Prevencio. "
A HART CAD study on 500 patients from the INOVA Heart and Heart Institute
in Virginia was also introduced to ACC. The study "Validation of Novel"
Biomarker-clinical score to predict the presence of obstructive coronary
Sickness ", led by Dr. Christopher deFilippi, Vice Chairman of the Board
Business. The results included a robust diagnostic odds ratio (DOR) of 4.69.
DOR is the ratio of the chances that the test is positive if the subject
has a disease in relation to the probability that the test will be positive if the
the subject does not have the disease. In addition, the study revealed a
AUC 0.81 in patients younger than 65, demonstrating accuracy for
younger patients.
Dr. deFilippi said: "There is a long-standing need for more
accurate and non-invasive cardiac tests, and we're excited to be working on
the next generation of diagnostic tests. Use the same algorithmic
model and threshold developed at Mbadachusetts General Hospital, these
Studies clearly confirm the accuracy of these tests in various
clinics and patient populations. "
Rhonda Rhyne, president and CEO of Prevencio, added: "These two
large external validation studies were crucial steps for the future
demonstrating the accuracy of our two lead tests. The studies will be
submitted to peer-reviewed journals, which will be in addition to our five
peer-reviewed journals. Rhyne concluded: "We are very grateful for
our ongoing collaboration with Dr. Januzzi, the researchers of the MGH, Myriad RBM,
and our investors, as well as our new partners at the University
Heart Center in Hamburg and INOVA Heart & Vascular Institute. "
Powered by AI, Prevencio revolutionizes blood tests for
heart disease. Using this original approach, the company has
developed six blood tests to date that significantly improve diagnoses
for a variety of complications related to the heart and blood vessels.
These tests are:
1. HART CAD ™ – Obstructive Coronary Artery Disease
diagnostic
2. HART CVE ™ – risk of heart attack, stroke or stroke
heart death
3. HART PAD ™ – Diagnosis of Peripheral Arterial Disease
4
HART AS ™ – diagnosis of stenosis of the aortic valve
5. HART AMP ™ – Risk of
amputation
6. HART AKI ™ – risk of acute kidney injury
The results of the HART test were presented at leading cardiovascular events.
meetings- (Scientific Sessions of the Congress of the European Society of Cardiology –
2016 and 2018, Scientific Sessions of the American College of Cardiology – 2017,
2018 and 2019, scientific sessions of the American Heart Association – 2017 and
Scientific Sessions of the American Diabetes Association – 2018) and
published in leading cardiology journals – (Journal of American
College of Cardiology – March 2017, American Journal of Cardiology
– July 2017 Open heart – November 2018 and Clinical cardiology
– June 2018 and January 2019).
About Prevencio, Inc .:
The value proposition of Prevencio is "Prevent what can be avoided", that is to say
avoid unnecessary procedures and the consequential side effects, as well as
improve patient outcomes and clinical trials through more accurate badysis
blood tests for cardiovascular diseases. Prevencio uses
Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers
+ Proprietary algorithms for cardiovascular diagnosis and
prognostic tests that are significantly more accurate than
standard resistance tests, individual biomarkers, genetic markers
and clinical risk scores. The company is headquartered in Kirkland,
Washington. For more information, visit www.PrevencioMed.com.
Prevencio – Prevent what can be avoided. ™
Safe Harbor Statement:
Except for the historical and factual information contained in this document, this
press release contains forward-looking statements, such as market needs,
acceptance rate, size and penetration, the accuracy of which is
necessarily subject to uncertainties and risks, including the
exclusive dependence on HART technology and various uncertainties
characteristic of developing companies. Society does not
Undertakes to update the information contained in this press release.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20190318005153/fr/
Source link
